KEY PREDICTIVE FACTORS OF AXITINIB (AG-013736)-INDUCED PROTEINURIA AND EFFICACY: A JAPANESE PHASE II STUDY IN PATIENTS WITH CYTOKINE-REFRACTORY METASTATIC RENAL CELL CANCER (MRCC)

被引：0
|
作者：
Tomita, Y. [1 ]
Uemura, H. [2 ]
Fujimoto, H. [3 ]
Kanayama, H. [4 ]
Shinohara, N. [5 ]
Nakazawa, H. [6 ]
Ozono, S. [7 ]
Naito, S. [8 ]
Akaza, H. [9 ]
机构：
[1] Yamagata Univ, Sch Med, Yamagata 99023, Japan
[2] Kinki Univ, Sch Med, Osaka 589, Japan
[3] Natl Canc Ctr, Tokyo, Japan
[4] Univ Tokushima, Fac Med, Tokushima 770, Japan
[5] Hokkaido Univ Hosp, Sapporo, Hokkaido 060, Japan
[6] Tokyo Womens Med Univ, Med Ctr E, Tokyo, Japan
[7] Hamamatsu Univ Sch Med, Hamamatsu, Shizuoka 4312102, Japan
[8] Kyushu Univ Hosp, Fukuoka 812, Japan
[9] Univ Tokyo, Adv Sci & Technol Res Ctr, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：282 / 282
页数：1
相关论文
共 50 条
  • [21] Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients
    Fujiwara, Yutaka
    Kiyota, Naomi
    Chayahara, Naoko
    Suzuki, Akiyuki
    Umeyama, Yoshiko
    Mukohara, Toru
    Minami, Hironobu
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (03) : 1055 - 1064
  • [22] A phase I/II study of axitinib (ag-013736) in combination with FOLFOX and bevacizumab in patients with metastatic gastrointestinal and other solid tumours
    Abhyankar, V
    Trowbridge, R.
    Robles, R.
    Tarazi, J.
    Kim, S.
    Tortorici, M.
    Hee, B.
    Rosbrook, B.
    Burgess, R.
    Sharma, S.
    ANNALS OF ONCOLOGY, 2008, 19 : 76 - 76
  • [23] An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma
    Seiji Naito
    Taiji Tsukamoto
    Michiyuki Usami
    Hiroyuki Fujimoto
    Hideyuki Akaza
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 1065 - 1070
  • [24] An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma
    Naito, Seiji
    Tsukamoto, Taiji
    Usami, Michiyuki
    Fujimoto, Hiroyuki
    Akaza, Hideyuki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (06) : 1065 - 1070
  • [25] Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone
    Dutcher, J. P.
    Wilding, G.
    Hudes, G. R.
    Stadler, W. M.
    Kim, S.
    Tarazi, J. C.
    Rosbrook, B.
    Rini, B. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [26] A PHASE I STUDY OF AXITINIB (AG-013736) PLUS FOLFOX CHEMOTHERAPY AND BEVACIZUMAB IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Abhyankar, V. V.
    Sharma, S.
    Trowbridge, R. C.
    Robles, R. L.
    Tarazi, J.
    Kim, S.
    Tortorici, M.
    Hee, B.
    Burgess, R. E.
    ANNALS OF ONCOLOGY, 2008, 19 : 128 - 128
  • [27] Continuous daily administration of sunitinib malate (SU11248) - A phase II study in patients (PTS) with cytokine-refractory metastatic renal cell carcinoma (MRCC)
    Escudier, Bernard
    Roigas, Jan
    Gillessen, Silke
    Srinivas, Sandhya
    Pisa, Pavel
    Vogelzang, Nicholas
    Fountzilas, George
    Peschel, Christian
    Baum, Charles M.
    De Mulder, Pieter
    ANNALS OF ONCOLOGY, 2006, 17 : 144 - 144
  • [28] Final Results of a Phase II Study of S-1 in Patients with Cytokine-refractory Metastatic Renal Cell Carcinoma
    Naito, Seiji
    Tatsugami, Katsunori
    Shinohara, Nobuo
    Tomita, Yoshihiko
    Mizokami, Atsushi
    Fujisawa, Masato
    Hashine, Katsuyoshi
    Nishikido, Masaharu
    Nakagawa, Masayuki
    Tsukamoto, Taiji
    Akaza, Hideyuki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 44 (02) : 122 - 126
  • [29] Efficacy and safety of single-agent axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): a phase II trial
    Von Pawel, J.
    Larson, T.
    Ou, S. I.
    Limentani, S. A.
    Sandler, A. B.
    Vokes, E. E.
    Kim, S.
    Liau, K. F.
    Bycott, P. W.
    Schiller, J. H.
    EJC SUPPLEMENTS, 2007, 5 (04): : 373 - 373
  • [30] A phase II study of S-1 for the treatment of cytokine-refractory metastatic renal cell carcinoma
    Naito, S.
    Eto, M.
    Shinohara, N.
    Tomita, Y.
    Fujisawa, M.
    Namiki, M.
    Nishikido, M.
    Usami, M.
    Tsukamoto, T.
    Akaza, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345